Cancer and scleroderma: recent insights

Morrisroe, Kathleen; Nikpour, Mandana

doi:10.1097/bor.0000000000000755

Cited by 13 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This delayed temporal relationship suggests that early BC onset might not be the trigger for the immune system to lead to SSc onset. In addition, it indicates that SSc might not be a paraneoplastic manifestation anticipating BC, as previously hypothesized [ 9 , 13 ]. Therefore, many factors should be considered in the common pathogenesis of these two disorders [ 18 ].…”

Section: Discussionsupporting

confidence: 58%

“…However, gastrointestinal and kidney involvement is also well known [ 1 , 2 ]. Previous studies have shown a 1.5-fold increase in cancer risk in SSc patients compared with the general population, especially lung cancer, hematological malignancies, and breast cancer (BC) [ 3 , 4 , 5 , 6 , 7 , 8 , 9 ]. Many theories have been put forward to explain this association: firstly, exposure to immunosuppressive therapies; secondly, genetic susceptibility to both malignancy and the development of autoimmune disease; and finally, a common inciting exposure or more likely a multifactorial pathogenic mechanism involving both genetic contributions as well as other cancer risk factors [ 10 , 11 , 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study

Toss

Spinella

Isca

et al. 2021

JPM

View full text Add to dashboard Cite

Systemic Sclerosis (SSc) is a chronic disease associated with a 1.5-fold increase in cancer risk, including lung cancer, hematological malignancies, and breast cancer (BC). This is a retrospective study aiming to explore the clinical and pathological features of BC developed by SSc patients. A total of 54.5% of patients developed BC before SSc (median interval: 5 years), whereas 45.5% of patients developed BC after SSc (median delay: 8 years). A total of 93.1% of patients were diagnosed with an early stage tumor. Among invasive carcinomas, 70.8% presented with a low Mib1, 8.3% with a tubular histotype, and 42.8% with a Luminal A-like phenotype. A total of 66.6% of patients underwent breast-conserving surgery and 55.5% RT. A total of 40% of patients developed interstitial lung disease after RT and 20% diffuse cutaneous SSc. The cause of death of the six deceased patients was PAH. A significant association was observed between the use of immunosuppressive therapy and diffuse skin extension, negative ACA, positive Anti-Scl-70, and interstitial lung disease, but not BC status. SSc patients developed BC at a good prognosis, suggesting a de-escalation strategy of cancer therapies. In particular, ionizing radiation and chemotherapeuticals should be limited to higher-risk cases. Finally, proper screening is mandatory in order to allow for early cancer detection in SSc patients.

show abstract

Section: Discussionsupporting

confidence: 58%

Section: Introductionmentioning

confidence: 99%

Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study

Toss

Spinella

Isca

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

“…SSc-specific autoantibodies may identify patients at high risk and play a role in the prognosis and triaging of patients who may require further cancer screening [24]. However, the best-known autoantibodies such as antitopoisomerase I and anticentromere are inconsistent in predicting risk for developing malignancy.…”

mentioning

confidence: 99%

Development of Two Types of Skin Cancer in a Patient with Systemic Sclerosis: a Case Report and Overview of the Literature

Ulutaş

Çomut

Çobankara

2021

Case Reports in Oncological Medicine

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is an uncommon rheumatic disease in which the underlying main histopathologic feature is a thickening of the skin due to excessive accumulation of collagen in the extracellular tissue. Fibrogenesis, chronic inflammation, and ulceration may eventually promote skin neoplasms. Although nonmelanoma skin cancer (NMSC) is the most frequent type, there have been restricted case reports and case series with skin cancers in SSc patients in the literature. Herein, we describe a 78-year-old woman diagnosed with diffuse cutaneous systemic sclerosis thirteen years ago and associated nonspecific interstitial pneumonia that was successfully treated with high cumulative doses of cyclophosphamide. She developed basal cell carcinoma and squamous cell carcinoma of the skin in the follow-up. She is still on rituximab treatment with stable interstitial lung disease as indicated by pulmonary function tests and high-resolution chest computed tomography. To our knowledge and a literature search, this is the first reported patient with SSc with two types of skin cancer. In this review, we also aimed to emphasize the relationship between SSc and skin cancer, and possible risk factors for SSc-related skin cancer.

show abstract

“…Furthermore, AKT2 and AKT3, as part of phosphoinositide 3-kinase (PI3K)/AKT/mTOR signaling pathway, have been associated with several adenocarcinomas [ 34 ]. As the risk for breast and lung carcinoma is increased in patients with SSc [ 35 , 36 , 37 , 38 ], we could hypothesize that anti-AKT antibodies might be relevant to define a subgroup of SSc patients with increased risk for cancer. Further studies are needed to explore the role of anti-AKT antibodies as biomarker candidates for fibrosis and risk of cancer in SSc patients.…”

Section: Discussionmentioning

confidence: 99%

Autoantibodies against PIP4K2B and AKT3 Are Associated with Skin and Lung Fibrosis in Patients with Systemic Sclerosis

Geroldinger‐Simic

Bayati

Pohjanen

et al. 2023

IJMS

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a rare autoimmune systemic disease that leads to decreased survival and quality of life due to fibrosis, inflammation, and vascular damage in the skin and/or vital organs. Early diagnosis is crucial for clinical benefit in SSc patients. Our study aimed to identify autoantibodies in the plasma of SSc patients that are associated with fibrosis in SSc. Initially, we performed a proteome-wide screening on sample pools from SSc patients by untargeted autoantibody screening on a planar antigen array (including 42,000 antigens representing 18,000 unique proteins). The selection was complemented with proteins reported in the literature in the context of SSc. A targeted antigen bead array was then generated with protein fragments representing the selected proteins and used to screen 55 SSc plasma samples and 52 matched controls. We found eleven autoantibodies with a higher prevalence in SSc patients than in controls, eight of which bound to proteins associated with fibrosis. Combining these autoantibodies in a panel could lead to the subgrouping of SSc patients with fibrosis. Anti-Phosphatidylinositol-5-phosphate 4-kinase type 2 beta (PIP4K2B)- and anti-AKT Serine/Threonine Kinase 3 (AKT3)-antibodies should be further explored to confirm their association with skin and lung fibrosis in SSc patients.

show abstract

Cancer and scleroderma: recent insights

Cited by 13 publications

References 42 publications

Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study

Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study

Development of Two Types of Skin Cancer in a Patient with Systemic Sclerosis: a Case Report and Overview of the Literature

Autoantibodies against PIP4K2B and AKT3 Are Associated with Skin and Lung Fibrosis in Patients with Systemic Sclerosis

Contact Info

Product

Resources

About